Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENPAD genotype-guided antithrombotic treatment in peripheral arterial disease
2020-004913-11Phase 4Active
- Sponsor
- Radboudumc
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel, rivaroxaban and aspirin in arteriosclerosis obliterans (2 arms), sponsored by Radboudumc. Primary endpoint: Occurrence of adverse clinical events at 24 months. Started Feb 2021; status: active.
02
Drugs
clopidogrelrivaroxabanaspirin
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on 2020-004913-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004913-11.